Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
Lung oligometastases
Prognostic factors
Sequential oligometastatic disease
Stereotactic body radiotherapy
Survival predictors
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
20
01
2022
accepted:
13
04
2022
pubmed:
3
5
2022
medline:
30
9
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
We report the retrospective data of a cohort of patients who received stereotactic body radiotherapy for pulmonary oligometastases, aiming to assess the clinical factors potentially affecting clinical outcomes. The present series reports the outcomes of a cohort of 71 patients with pulmonary oligometastases with no extrapulmonary disease. All patients were treated with stereotactic body radiotherapy (SBRT) performed with volumetric modulated arc therapy-image guided radiotherapy (VMAT-IGRT) to up to five secondary lesions. Survival estimates were performed using the Kaplan-Meier method. A total of 98 lesions in 71 patients were treated from February 2014 to August 2020. The most frequent histologies were colorectal in 37.7%, lung cancer in 44.8%, head and neck cancer in 8.1%, and other in 9.4%. Median age was 71 years (range 32-93 years). Concurrent systemic therapy was administered in 32.3%. SBRT was delivered to a median total dose of 60 Gy (range 55-70 Gy) in 3-10 fractions for a median BED
Identifiants
pubmed: 35499694
doi: 10.1007/s00066-022-01951-0
pii: 10.1007/s00066-022-01951-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
934-939Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Herold CJ, Bankier AA, Fleischmann D (1996) Lung metastases. Eur Radiol 6(5):596–606
doi: 10.1007/BF00187656
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10
doi: 10.1200/JCO.1995.13.1.8
Filippi AR, Guerrera F, Badellino S, Ceccarelli M, Castiglione A, Guarneri A et al (2016) Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung Oligometastases from colorectal Cancer. J Clin Oncol 28(8):505–512
doi: 10.1016/j.clon.2016.02.001
Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, Maat A, van Klaveren RJ, van der Holt B et al (2015) Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys 91(2):337–343
doi: 10.1016/j.ijrobp.2014.10.021
Figlia V, Mazzola R, Cuccia F, Alongi F, Mortellaro G, Cespuglio D, Cucchiara T, Iacoviello G, Valenti V, Molino M, Verderame F, Matranga D, Casto AL, Ferrera G (2018) Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience. Radiol Med 123(6):406–414. https://doi.org/10.1007/s11547-018-0858-7
doi: 10.1007/s11547-018-0858-7
pubmed: 29455424
Cuccia F, Mortellaro G, Mazzola R, Donofrio A, Valenti V, Tripoli A, Matranga D, Casto LA, Failla G, Di Miceli G, Ferrera G (2020) Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy. J Geriatr Oncol 11(3):475–481. https://doi.org/10.1016/j.jgo.2019.05.002
doi: 10.1016/j.jgo.2019.05.002
pubmed: 31122872
Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi MA, Rigo M, Mazzola R, Perna M, Scotti V, Fodor A, Iurato A, Pasqualetti F, Gadducci G, Chiesa S, Niespolo RM, Bruni A, Alicino G, Frassinelli L, Borghetti P, Di Marzo A, Ravasio A, De Bari B, Sepulcri M, Aiello D, Mortellaro G, Sangalli C, Franceschini M, Montesi G, Aquilanti FM, Lunardi G, Valdagni R, Fazio I, Corti L, Vavassori V, Maranzano E, Magrini SM, Arcangeli S, Valentini V, Paiar F, Ramella S, Di Muzio NG, Livi L, Jereczek-Fossa BA, Osti MF, Scorsetti M, Alongi F (2021) A multicenter LArge retrospectIve daTabase on the personalization of Stereotactic ABlative Radiotherapy use in lung metastases from colon-rectal cancer: the LaIT-SABR study. Radiother Oncol. https://doi.org/10.1016/j.radonc.2021.10.023
doi: 10.1016/j.radonc.2021.10.023
pubmed: 34748855
Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, Joyce N, Schell MC, Milano MT (2014) Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis 6(4):369–374. https://doi.org/10.3978/j.issn.2072-1439.2013.12.03
doi: 10.3978/j.issn.2072-1439.2013.12.03
pubmed: 24688781
pmcid: 3968553
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830–2838. https://doi.org/10.1200/JCO.20.00818
doi: 10.1200/JCO.20.00818
pubmed: 32484754
pmcid: 7460150
Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, Johnston M, McCormack P, Pass H, Putnam JB Jr, International Registry of Lung Metastases (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113(1):37–49. https://doi.org/10.1016/s0022-5223(97)70397-0
doi: 10.1016/s0022-5223(97)70397-0
pubmed: 9011700
Li S, Nie S, Li Z, Che G (2019) Is stereotactic radiotherapy equivalent to metastasectomy in patients with pulmonary oligometastases? Interact CardioVasc Thorac Surg 29(4):544–550. https://doi.org/10.1093/icvts/ivz133
doi: 10.1093/icvts/ivz133
pubmed: 31180484
Lindsay DP, Caster JM, Wang K, Myung JH, Chen RC, Chera B et al (2017) Nanotechnology-based quantification of circulating tumor cells in oligometastatic patients undergoing definitive radiation therapy. Int J Radiat Oncol Biol Phys 99(2):S51
doi: 10.1016/j.ijrobp.2017.06.130
Zhao Y, Khawandanh E, Thomas S, Zhang S, Dunne EM, Liu M, Schellenberg D (2020) Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors. Radiat Oncol 15(1):61. https://doi.org/10.1186/s13014-020-01491-w
doi: 10.1186/s13014-020-01491-w
pubmed: 32106868
Hanna GG, Murray L, Patel R et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol 30(1):5–14. https://doi.org/10.1016/j.clon.2017.09.007
doi: 10.1016/j.clon.2017.09.007
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U (2015) LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 88(1051):20150036. https://doi.org/10.1259/bjr.20150036
doi: 10.1259/bjr.20150036
pubmed: 25873481
pmcid: 4628529
Nicosia L, Cuccia F, Mazzola R, Ricchetti F, Figlia V, Giaj-Levra N, Rigo M, Tomasini D, Pasinetti N, Corradini S, Ruggieri R, Alongi F (2020) Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol. https://doi.org/10.1007/s00066-020-01627-7
doi: 10.1007/s00066-020-01627-7
pubmed: 33242139
Greco C, Pares O, Pimentel N, Louro V, Morales J, Nunes B, Castanheira J, Oliveira C, Silva A, Vaz S, Costa D, Zelefsky M, Kolesnick R, Fuks Z (2019) Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy. Int J Radiat Oncol Biol Phys 104(3):593–603. https://doi.org/10.1016/j.ijrobp.2019.02.033
doi: 10.1016/j.ijrobp.2019.02.033
pubmed: 30797891
Kalinauskaite GG, Tinhofer II, Kufeld MM, Kluge AA, Grün AA, Budach VV, Senger CC, Stromberger CC (2020) Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases. BMC Cancer 20(1):404. https://doi.org/10.1186/s12885-020-06892-4
doi: 10.1186/s12885-020-06892-4
pubmed: 32393261
pmcid: 7216666
Niibe Y, Yamamoto T, Onishi H, Yamashita H, Katsui K, Matsumoto Y, Oh RJ, Aoki M, Shintani T, Yamada K, Kobayashi M, Ozaki M, Manabe Y, Yahara K, Nishikawa A, Kakuhara H, Yamamoto K, Inoue T, Takada YU, Nagata K, Suzuki O, Terahara A, Jingu K (2020) Pulmonary oligometastases treated by stereotactic body radiation therapy: a nationwide survey of 1,378 patients. Anticancer Res 40(1):393–399. https://doi.org/10.21873/anticanres.13965
doi: 10.21873/anticanres.13965
pubmed: 31892592
Yamamoto T, Niibe Y, Matsumoto Y, Onishi H, Aoki M, Nishikawa A, Oh RJ, Shintani T, Yahara K, Ozaki M, Manabe Y, Jingu K (2020) Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma. J Radiat Res 61(6):935–944. https://doi.org/10.1093/jrr/rraa071
doi: 10.1093/jrr/rraa071
pubmed: 32940330
pmcid: 7674693